Publications by authors named "Francois Wilhelm"

Claim this Profile
R
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Guillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, Maria R Baer, Mikkael A Sekeres, Francois E Wilhelm

Lancet Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.
Bishoy Faltas, David M Goldenberg, Allyson J Ocean, Serengulam V Govindan, Francois Wilhelm

Clin Genitourin Cancer· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Lewis R Silverman, Peter Greenberg, Azra Raza, Matthew J Olnes, James F Holland, Francois Wilhelm

Hematol Oncol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
Daniel W Bowles, Jennifer R Diamond, Elaine T Lam, Colin D Weekes, David P Astling, Francois Wilhelm

Clin Cancer Res· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
Ryan T Anderson, Stephen B Keysar, Daniel W Bowles, Magdalena J Glogowska, David P Astling, Francois Wilhelm

Mol Cancer Ther· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.
Rami S Komrokji, Azra Raza, Jeffrey E Lancet, Chen Ren, David Taft, Francois Wilhelm

Br J Haematol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer.
Takao Ohnuma, Deborah Lehrer, Chen Ren, Sool Yeon Cho, Manoj Maniar, Francois Wilhelm

Am J Cancer Res· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Matthew J Olnes, Aarthie Shenoy, Barbara Weinstein, Loretta Pfannes, Kelsey Loeliger, Francois Wilhelm

Leuk Res· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Wen Wee Ma, Wells A Messersmith, Grace K Dy, Colin D Weekes, Amy Whitworth, Francois Wilhelm

Clin Cancer Res· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Mahesh Seetharam, Alice C Fan, Mai Tran, Liwen Xu, John P Renschler, Francois Wilhelm

Leuk Res· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
John A Glaspy, Veena Charu, Donghan Luo, Victor Moyo, Marc Kamin, Francois E Wilhelm

Cancer· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
Vernon P Montoya, John Xie, Denise Williams, Richard C Woodman, Francois E Wilhelm

Support Care Cancer· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An extended dosing regimen of epoetin alfa 60,000 units every 2 weeks in anemic patients with cancer receiving chemotherapy.
Stephanie A Gregory, John Xie, Tomek Szczudlo, Denise Williams, Richard C Woodman, Francois E Wilhelm

Support Cancer Ther· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label pilot study to evaluate a flexible dosing regimen of epoetin alfa for the treatment of chemotherapy-induced anemia: 60,000 units weekly followed by 60,000 units every 2 weeks.
Prabhakara K Reddy, Denise Williams, Francois E Wilhelm

Support Cancer Ther· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
David H Henry, Lucio N Gordan, Veena Charu, Francois E Wilhelm, Denise Williams

Curr Med Res Opin· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.
Jan Albert Kuivenhoven, Greetje J de Grooth, Hitoshi Kawamura, Anke H Klerkx, Francois Wilhelm

Am J Cardiol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis